GenBioPro Sues FDA to Keep Generic Mifepristone on the Market
GenBioPro—the pharmaceutical company that makes a generic version of the abortion pill mifepristone—sued the U.S. Food and Drug Administration (FDA) on Wednesday, April 19, in Maryland federal court, where the agency is headquartered. The suit seeks an order to compel the FDA to allow GenBioPro to continue to sell the medication in the United States.
“Once a drug has been through the rigorous FDA review process and received approval, federal law protects the right to market the drug,” said GenBioPro CEO Evan Massingill. “GenBioPro will use all regulatory and legal tools to protect access to mifepristone for patients and providers.”
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed